These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33226651)

  • 21. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
    Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
    Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
    Sasson AN; Ananthakrishnan AN
    Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
    Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
    Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy.
    Moses J; Lambert-Jenkins K; Momotaz H; Sattar A; Debanne SM; Splawski J; Sferra TJ
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1228-1233. PubMed ID: 31498282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation Between Ultrasonographic Response and Anti-Tumor Necrosis Factor Drug Levels in Crohn's disease.
    Han ZM; Elodie WH; Yan LH; Xu PC; Zhao XM; Zhi FC
    Ther Drug Monit; 2022 Oct; 44(5):659-664. PubMed ID: 35427284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.
    Meroni PL; Valentini G; Ayala F; Cattaneo A; Valesini G
    Autoimmun Rev; 2015 Sep; 14(9):812-29. PubMed ID: 25985765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
    Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Bodini G; Demarzo MG; Djahandideh A; Ziola S; Risso P; Bertani L; Baldissarro I; Testa T; Marchi S; Savarino E; Giannini EG
    Eur J Gastroenterol Hepatol; 2022 Apr; 34(4):382-388. PubMed ID: 34334710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
    Gofin Y; Matar M; Shamir R; Assa A
    Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
    Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
    Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.